Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Com-COV
  ISRCTN69254139		 RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
-/- inconclusive
    Reindl-Schwaighofer RCTJanssen AD26 vaccine (JNJ-78436735)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
    		100/101 inconclusive
      MixNMatch Study
              NCT04889209      		 OBSJanssen AD26 vaccine (JNJ-78436735)mRNA vaccineCOVID-19 prophylaxis (excluding children)NA
      		-/- inconclusive
        Botton (EPI-PHARE) OBSJanssen AD26 vaccine (JNJ-78436735)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
        		-/- safety concern
        • statistically significant 5.7-fold increase in hospitalization

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons